JP6790304B2 - Ｂｔｌａアゴニスト抗体およびその使用 - Google Patents

Ｂｔｌａアゴニスト抗体およびその使用 Download PDF

Info

Publication number
JP6790304B2
JP6790304B2 JP2020511876A JP2020511876A JP6790304B2 JP 6790304 B2 JP6790304 B2 JP 6790304B2 JP 2020511876 A JP2020511876 A JP 2020511876A JP 2020511876 A JP2020511876 A JP 2020511876A JP 6790304 B2 JP6790304 B2 JP 6790304B2
Authority
JP
Japan
Prior art keywords
seq
antibody
amino acid
acid sequence
btla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020511876A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518288A (ja
Inventor
シェイン・クルメン・アットウェル
ビクター・エイチ・オブング
アンドリュー・チャールズ・ベンデル
Original Assignee
イーライ リリー アンド カンパニー
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー, イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2020518288A publication Critical patent/JP2020518288A/ja
Application granted granted Critical
Publication of JP6790304B2 publication Critical patent/JP6790304B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020511876A 2017-05-19 2018-05-11 Ｂｔｌａアゴニスト抗体およびその使用 Active JP6790304B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19
US62/508,510 2017-05-19
PCT/US2018/032218 WO2018213113A1 (en) 2017-05-19 2018-05-11 Btla agonist antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020184527A Division JP7072622B2 (ja) 2017-05-19 2020-11-04 Ｂｔｌａアゴニスト抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2020518288A JP2020518288A (ja) 2020-06-25
JP6790304B2 true JP6790304B2 (ja) 2020-11-25

Family

ID=62245543

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511876A Active JP6790304B2 (ja) 2017-05-19 2018-05-11 Ｂｔｌａアゴニスト抗体およびその使用
JP2020184527A Active JP7072622B2 (ja) 2017-05-19 2020-11-04 Ｂｔｌａアゴニスト抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020184527A Active JP7072622B2 (ja) 2017-05-19 2020-11-04 Ｂｔｌａアゴニスト抗体およびその使用

Country Status (26)

Country Link
US (2) US10604573B2 (https=)
EP (1) EP3625257A1 (https=)
JP (2) JP6790304B2 (https=)
KR (3) KR20220158847A (https=)
CN (3) CN110621699B (https=)
AR (1) AR111752A1 (https=)
AU (2) AU2018269585B2 (https=)
BR (1) BR112019021547A2 (https=)
CA (2) CA3184628A1 (https=)
CL (1) CL2019003215A1 (https=)
CO (1) CO2019012756A2 (https=)
CR (1) CR20190521A (https=)
DO (1) DOP2019000293A (https=)
EA (1) EA201992460A1 (https=)
EC (1) ECSP19082184A (https=)
JO (1) JOP20190261A1 (https=)
MA (1) MA49133A (https=)
MX (1) MX381033B (https=)
MY (2) MY197425A (https=)
NZ (1) NZ758360A (https=)
PE (1) PE20191843A1 (https=)
PH (1) PH12019502575A1 (https=)
SA (1) SA519410534B1 (https=)
TW (4) TWI804044B (https=)
WO (1) WO2018213113A1 (https=)
ZA (1) ZA201906954B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
GB202008860D0 (en) * 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
WO2022087441A2 (en) * 2020-10-23 2022-04-28 Anaptysbio, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
MX2024009326A (es) * 2022-01-29 2024-08-06 Hifibio Inc Anticuerpos anti-btla y usos de los mismos en el tratamiento del cancer.
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells
WO2026053130A1 (en) * 2024-09-03 2026-03-12 Mirobio Limited Anti-btla antibodies and uses of the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
WO2004039394A1 (en) * 2002-10-25 2004-05-13 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
KR20090088891A (ko) * 2006-11-15 2009-08-20 메다렉스, 인코포레이티드 비티엘에이에 대한 인간 단일클론 항체 및 이용 방법
CN102762593B (zh) * 2009-07-31 2015-05-20 梅达雷克斯有限责任公司 抗btla的完全人抗体
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
WO2014183885A1 (en) * 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
EP3288587A4 (en) * 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
KR102815803B1 (ko) 2015-12-02 2025-06-05 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체

Also Published As

Publication number Publication date
DOP2019000293A (es) 2019-12-15
AR111752A1 (es) 2019-08-14
EP3625257A1 (en) 2020-03-25
CN110621699A (zh) 2019-12-27
WO2018213113A1 (en) 2018-11-22
SA519410534B1 (ar) 2023-11-08
NZ758360A (en) 2022-10-28
MX381033B (es) 2025-03-12
BR112019021547A2 (pt) 2020-05-12
TWI747043B (zh) 2021-11-21
ECSP19082184A (es) 2019-11-30
CN117402244A (zh) 2024-01-16
TW201904991A (zh) 2019-02-01
AU2021277743A1 (en) 2021-12-23
MA49133A (fr) 2020-03-25
ZA201906954B (en) 2021-06-30
KR102294051B1 (ko) 2021-08-27
TW202334237A (zh) 2023-09-01
MY198277A (en) 2023-08-18
JP7072622B2 (ja) 2022-05-20
PE20191843A1 (es) 2019-12-31
CR20190521A (es) 2020-01-06
US11396545B2 (en) 2022-07-26
US10604573B2 (en) 2020-03-31
EA201992460A1 (ru) 2020-03-18
PH12019502575A1 (en) 2020-07-13
TW202233681A (zh) 2022-09-01
TWI804044B (zh) 2023-06-01
CN110621699B (zh) 2023-10-31
CA3184628A1 (en) 2018-11-22
CO2019012756A2 (es) 2020-01-17
JOP20190261A1 (ar) 2019-11-05
KR20210106033A (ko) 2021-08-27
US20180334502A1 (en) 2018-11-22
JP2021019642A (ja) 2021-02-18
JP2020518288A (ja) 2020-06-25
CA3064518A1 (en) 2018-11-22
CN117402245A (zh) 2024-01-16
MX2019013604A (es) 2019-12-18
TW201946932A (zh) 2019-12-16
MY197425A (en) 2023-06-16
KR20220158847A (ko) 2022-12-01
AU2018269585B2 (en) 2021-09-02
US20200239578A1 (en) 2020-07-30
KR20190140969A (ko) 2019-12-20
AU2018269585A1 (en) 2019-10-31
CL2019003215A1 (es) 2020-04-13
TWI677504B (zh) 2019-11-21

Similar Documents

Publication Publication Date Title
JP7072622B2 (ja) Ｂｔｌａアゴニスト抗体およびその使用
TWI708787B (zh) Pd-1促效劑抗體及其用途
CN106554417B (zh) 抗ox40抗体和使用其的方法
JP7843516B2 (ja) 抗ヒト胸腺間質性リンパ球新生因子抗体及びその製造方法と使用
JP2019534282A (ja) 抗ｉｌ−３３抗体およびその使用
CN112739422B (zh) Cd200r激动剂抗体及其用途
JP2023515480A (ja) 抗ｉｌ－２抗体、その抗原結合断片及びその医薬用途
KR20250127162A (ko) 항-baff 항체를 포함하는 이중특이적 결합 단백질 및 이의 용도
EA043345B1 (ru) Антитела-агонисты btla и их применение
WO2026086834A1 (zh) 抗ox40抗体在治疗皮炎疾病中的用途
TW202434625A (zh) Lag-3及pd-1/lag-3抗體
AU2023410319A1 (en) Anti-human cx3cr1 antibody
CN120173110A (zh) 一种靶向cxcr6的抗体及其应用
CN121910866A (zh) 抗ox40抗体在治疗皮炎疾病中的用途
HK40082498A (en) Anti-il-2 antibody, and antigen-binding fragment thereof and medical use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201104

R150 Certificate of patent or registration of utility model

Ref document number: 6790304

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250